Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.

Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH, Park JE, Jeon HR, Oh YJ, Yi JE, Jung HO, Youn HJ, Kim DW.

Cancer Res Treat. 2015 Oct;47(4):937-42. doi: 10.4143/crt.2013.155. Epub 2014 Nov 17.

2.

Reversible dasatinib-related pulmonary arterial hypertension in a CML patient.

Nagasaki J, Aoyama Y, Nomoto Y, Ido K, Ichihara H, Mugitani A.

Rinsho Ketsueki. 2016 May;57(5):618-23. doi: 10.11406/rinketsu.57.618. Review. Japanese.

PMID:
27263788
3.

[Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].

Edahiro Y, Takaku T, Konishi H, Tsukune Y, Fujioka I, Takasu K, Gotoh A, Daida H, Komatsu N.

Rinsho Ketsueki. 2017;58(11):2213-2218. doi: 10.11406/rinketsu.58.2213. Japanese.

PMID:
29212971
4.

Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.

Morishita S, Hagihara M, Itabashi M, Ishii Y, Yamamoto W, Numata A, Motohashi K, Matsumoto K, Fujisawa S, Nakajima H.

Rinsho Ketsueki. 2016 Aug;57(8):999-1003. doi: 10.11406/rinketsu.57.999. Review. Japanese.

PMID:
27599415
5.

Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.

Sano M, Saotome M, Urushida T, Katoh H, Satoh H, Ohnishi K, Hayashi H.

Intern Med. 2012;51(17):2337-40. Epub 2012 Sep 1.

6.

[Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].

Jin J, Xu XM, Wang C.

Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):83-7. doi: 10.3760/cma.j.issn.1001-0939.2016.02.002. Review. Chinese.

PMID:
26879609
7.

[Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].

Liu B, Wang Y, Mi Y, Wang J.

Zhonghua Xue Ye Xue Za Zhi. 2014 Jul;35(7):581-6. doi: 10.3760/cma.j.issn.0253-2727.2014.07.002. Review. Chinese.

PMID:
25052596
8.

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A.

Am J Hematol. 2015 Nov;90(11):1060-4. doi: 10.1002/ajh.24174. Epub 2015 Oct 12. Review.

9.

Dasatinib-induced pulmonary arterial hypertension - A rare late complication.

Ibrahim U, Saqib A, Dhar V, Odaimi M.

J Oncol Pharm Pract. 2019 Apr;25(3):727-730. doi: 10.1177/1078155217753740. Epub 2018 Jan 17.

PMID:
29343154
10.

Pulmonary arterial hypertension in patients treated by dasatinib.

Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M.

Circulation. 2012 May 1;125(17):2128-37. doi: 10.1161/CIRCULATIONAHA.111.079921. Epub 2012 Mar 26.

PMID:
22451584
11.

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.

Skride A, Sablinskis M, Sablinskis K, Lesina K, Lejnieks A, Lejniece S.

J Med Case Rep. 2017 Dec 29;11(1):362. doi: 10.1186/s13256-017-1515-9.

12.

Is dasatinib-related pulmonary hypertension a clinical concern?

Szmit S.

Future Oncol. 2015 Sep;11(18):2491-4. doi: 10.2217/fon.15.170. Epub 2015 Aug 17. No abstract available.

PMID:
26278893
13.

Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.

Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S.

Eur Respir J. 2011 Jul;38(1):218-20. doi: 10.1183/09031936.00154210. No abstract available.

14.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

15.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

16.

[Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].

Makeeva LM, Emelina EI, Gendlin GE, Nikitin IG, Vasyuk YA, Nesvetov VV.

Kardiologiia. 2017 Apr;57(S4):53-60. Russian.

PMID:
29466183
17.

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Rasheed W, Flaim B, Seymour JF.

Leuk Res. 2009 Jun;33(6):861-4. doi: 10.1016/j.leukres.2008.09.026. Epub 2008 Nov 4. No abstract available.

PMID:
18986702
18.

[A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].

Sato M, Watanabe S, Aoki N, Asakawa K, Moriyama H, Oshima Y, Koya T, Okazuka K, Kikuchi T.

Gan To Kagaku Ryoho. 2018 May;45(5):851-854. Japanese.

PMID:
30026450
19.

Reversible pre-capillary pulmonary hypertension due to dasatinib.

Buchelli Ramirez HL, Álvarez Álvarez CM, Rodríguez Reguero JJ, García Clemente MM, Casan Clarà P.

Respir Care. 2014 May;59(5):e77-80. doi: 10.4187/respcare.02692. Epub 2013 Oct 22.

20.

[Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment].

Watanuki S, Kikuchi T, Toyama T, Abe R, Nakayama H, Karigane D, Shimizu T, Kikuchi J, Matsumoto K, Yasuoka H, Kataoka M, Okamoto S, Mori T.

Rinsho Ketsueki. 2018;59(2):174-177. doi: 10.11406/rinketsu.59.174. Japanese.

PMID:
29515069

Supplemental Content

Support Center